Subscribe To

Price Alert Latest News Economic Calendar News

ICPT / Intercept Pharmaceuticals stock tumbles toward 11-month low after disappointing FDA committee vote

Shares of Intercept Pharmaceuticals Inc. ICPT, -1.95% tumbled 15.2% toward an 11-month low in premarket trading Monday, after the biopharmaceutical company said a U.S. Food and Drug Administration committee voted to “defer approval” for its treatment of pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH). The company said 15 of 16 FDA committee members voted to defer approve until clinical outcome data from a trial are submitted and reviewed, and 12 of 16 members voted “no” on the question of whether current efficacy and safety data suggests benefits of the treatment (OCA 25 milligram) outweigh risks in NASH patients. Read More

Demo Live Account See Partner Details

Content Topics

Intercept

Pharmaceuticals

Stock

Tumbles

Toward

11 Month

11 month

Disappointing

Committee

ICPT

Posted: May 22 2023, 07:38

Author Name: Market Watch

ICPT News

By Zacks Investment Research
October 31, 2023

Will Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should Know

Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with

By Zacks Investment Research
September 27, 2023

Intercept (ICPT) Stock Jumps 79.2%: Will It Continue to Soar?

Intercept (ICPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help th

By The Motley Fool
September 26, 2023

Why Intercept Pharmaceuticals Stock Is Skyrocketing Today

The stock is exploding following an announcement that it's on track to be acquired. Alfasigma is poised to buy Intercept at a price of $19 per share.

By InvestorPlace
September 26, 2023

Why Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today?

Amid a rough day on Wall Street, Intercept Pharmaceuticals (NASDAQ: ICPT ) represented a bright spot, with shares swinging up 75% before slightly addi

By Proactive Investors
September 26, 2023

Intercept Pharmaceuticals stock soars on Alfasigma acquisition deal

Intercept Pharmaceuticals (NASDAQ:ICPT) Inc shares surged 79% to $18.64 in late-morning trading on Tuesday after the biopharmaceutical company specia

By Market Watch
September 26, 2023

Intercept Pharmaceuticals' stock set to soar after Alfasigma buyout deal for an 82% premium

Shares of Intercept Pharmaceuticals Inc. ICPT, -0.38% were set to soar Tuesday, after the biopharmaceutical company announced an agreement to be acqui

By Zacks Investment Research
August 2, 2023

Intercept (ICPT) Q2 Earnings Top Estimates, Revenues Up Y/Y

Intercept (ICPT) reports a lower net loss and beats on revenues in the second quarter. The company also updates its guidance for its lead drug, Ocaliv

By Seeking Alpha
August 2, 2023

Intercept Pharmaceuticals, Inc. (ICPT) Q2 2023 Earnings Call Transcript

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Nareg Sagherian - Execu

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.